Default Category
-
Megaprojects & the Role of the Public: Germany's Embattled 'Stuttgart 21' Rail Project
Varley, Pamela; Mayne, QuintonCase HBS-KS1130-EEconomicsIn February 2010, Germany's national railway broke ground on a project that had been under negotiation for more than 20 years-the Stuttgart segment of the European Magistrale, a 930-mile cross-Europe high-speed rail line that would one day extend from Paris through Munich and Vienna to Budapest and Bratislava. At long last, the German national railway, the state of Baden-W rttemberg, and the city of Stuttgart had come to agreement on the routing...Starting at €8.20
-
Dr. Reddy's Laboratories (B)
Jean-Louis Schaan; Ramasastry ChandrasekharCase IVEY-9B08M065-EStrategyThis supplement to Dr. Reddy's Laboratories (A), product # 9B08M064, looks at the two years post-acquisition and examines a major risk which, as it unfolded, brought the viability of the business model into question.Starting at €5.74
-
Dr. Reddy's Laboratories (A)
Jean-Louis Schaan; Ramasastry ChandrasekharCase IVEY-9B08M064-EStrategyDr. Reddy's Laboratories (Dr. Reddy's), a large pharmaceutical company in India, is trying to acquire the fourth largest generics manufacturer in Germany. Dr. Reddy's quoted $570 million in a competitive bidding situation. The company's chief negotiator is getting ready to close the deal if selected. Students will examine the issues for the chief negotiator, such as: is the price right, is the fit strategic, will the acquisition add value, how ca...Starting at €8.20
-
Dr. Reddy's Laboratories (A) (Spanish version)
Jean-Louis Schaan; Ramasastry ChandrasekharCase IVEY-9B08MS64StrategyDr. Reddy's Laboratories (Dr. Reddy's), a large pharmaceutical company in India, is trying to acquire the fourth largest generics manufacturer in Germany. Dr. Reddy's quoted $570 million in a competitive bidding situation. The company's chief negotiator is getting ready to close the deal if selected. Students will examine the issues for the chief negotiator, such as: is the price right, is the fit strategic, will the acquisition add value, how ca...Starting at €8.20
-
Dr. Reddy's Laboratories (B) (Spanish version)
Jean-Louis Schaan; Ramasastry ChandrasekharCase IVEY-9B08MS65StrategyThis supplement to Dr. Reddy's Laboratories (A), product # 9B08M064, looks at the two years post-acquisition and examines a major risk which, as it unfolded, brought the viability of the business model into question.Starting at €5.74
-
Schibsted (A): Should We Launch 20 Minutes
Jean-Louis Schaan; Jordan MitchellCase IVEY-9B07M019-EStrategyThe executive vice-president of newspapers for Schibsted was about to meet with his colleagues to discuss the company's plan to release an internally developed free daily newspaper concept called 20 Minutes. Over the past couple of years, Schibsted's executive team had kept a watchful eye on the free newspaper industry, which was enjoying tremendous popularity. Earlier in the year, Schibsted had launched Avis 1, a free paper with direct delivery ...Starting at €8.20